The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer

Published:2021-10 Issue: Volume:160 Page:136-151
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Melosky Barbara^ORCID,Wheatley-Price Paul,Juergens Rosalyn A.,Sacher Adrian,Leighl Natasha B.,Tsao Ming-Sound^ORCID,Cheema Parneet,Snow Stephanie^ORCID,Liu Geoffrey,Card Paul B.,Chu Quincy

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference154 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008

3. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion;Chu;Ther. Adv. Med. Oncol.,2020

4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med.,2004

5. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuronatin Promotes the Progression of Non-small Cell Lung Cancer by Activating the NF-κB Signaling;Current Cancer Drug Targets;2024-11

2. The genomic landscape of lung cancer in never-smokers from the Women’s Health Initiative;JCI Insight;2024-07-25

3. Antibody MYH9 and Antibiotic Lidamycin Inhibit the Growth and Proliferation of Lung Cancer Cells and Induce Their Apoptosis;Molecular Biotechnology;2024-07-13

4. The chain mediating effect of spiritual well‐being and anticipatory grief between benefit finding and meaning in life of patients with advanced lung cancer: Empirical research quantitative;Nursing Open;2024-06-28

5. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication;ESMO Open;2024-06